Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RI-ACT
- Development stage
- Preclinical
- Lead developer
- NGM Biopharmaceuticals
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
RI-ACT™ (Rapidly Internalizing Receptor-Antibody Conjugate Technology) is a proprietary preclinical-stage bispecific antibody-drug conjugate (ADC) platform developed by NGM Biopharmaceuticals for the treatment of solid tumors. The architecture utilizes a bispecific antibody where one arm targets a tumor-associated antigen (TAA) to ensure specificity, while the second arm binds to a rapidly internalizing receptor (RIR). This dual-targeting approach is designed to exploit the high-speed endocytosis of the RIR to facilitate the efficient delivery and internalization of cytotoxic payloads into cancer cells, thereby enhancing tumor cell killing and potentially overcoming limitations of conventional ADCs that rely on slowly internalizing antigens.
- Brand names
- RI-ACT
- Other names
- Bi-specific Rapidly Internalizing ADC Cancer Therapeutics
02
Targets
MAGEA8 (Melanoma-associated antigen 8)
Beyond the preview
Go deeper on RI-ACT.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RI-ACT.